litmus-api

<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"> <html xmlns="http://www.w3.org/1999/xhtml"> <head> <meta http-equiv="Content-Type" content="text/html; charset=utf-8" /> <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1"/> <title>BioOncology</title> <style type="text/css"> /*************************************** GLOBAL STYLES ****************************************/ .main-td{ font-family: helvetica, arial, sans-serif; font-size: 12px; color: #4D4D4F; line-height: 16px; } .h1, .h3, .h4 { font-weight: bold; } .h1 { font-size: 21px; color: #ffffff; line-height: 25px; } .h2 { font-size: 13px; color: #ffffff; line-height: 17px; } .h3 { font-size: 14px; color: #711471; line-height: 18px; padding-bottom: 5px; } .h4 { font-size: 12px; color: #711471; } .p, .ul { padding-bottom: 15px; } .ul .li, .footnote .li { padding-right: 5px; width: 1px; } .ul .sub { padding: 0 0 0 10px; } .hr { background-color: #b3b3b3; display: block; font-size: 0px; height: 1px; line-height: 0px; padding: 0; } /* horizontal rule */ .footnote, .footnote table { font-size: 10px; line-height: 13px; } sup { line-height: 0; font-size: 75%; } .webversion { color: #4D4D4F; font-size:10px; text-decoration:underline; } .linkDivider { font-weight: lighter; padding-left: 3px; padding-right: 3px; } .no-underline { text-decoration: none; } .underline { text-decoration: underline; } .bold { font-weight: bold; } .no-link { color: #4D4D4F; text-decoration: none; cursor: text; } a, .purple { color: #711471; } .blue { color: #005596;} .light-gray { color: #a0a0a0;} .button a, .footer a { color: #ffffff; text-decoration: none;} .legal-info { font-size: 10px; line-height: 13px;} .legal-info .p, .address { padding-top: 5px; padding-bottom: 5px; } .safety .button a { font-size: 10px; line-height: 13px;} .border { border: 1px solid #94ADC5; } .arrow { font-size:16px; font-family: serif;} .white { color: #ffffff;} .bt { border-top: 1px solid #a6a6a6;} .callout .ul table, .callout .ul { font-size: 11px; } .callout .ul { padding-bottom: 0;} .callout .ul td{ padding-bottom: 15px;} .callout .ul tr:last-child td { padding-bottom: 0;} .footnote td { padding-bottom: 10px;} .image { font-size: 0; line-height: 0; } .chart table { font-size: 10px; color: #711471; line-height: 12px; } .small-font { font-size: 8px; line-height: 10px;} /*************************************** SPACING STYLES ****************************************/ .p0 { padding-top:0;padding-right:0;padding-bottom:0;padding-left:0; } .p5 { padding-top:5px;padding-right:5px;padding-bottom:5px;padding-left:5px; } .p10 { padding-top:10px;padding-right:10px;padding-bottom:10px;padding-left:10px; } .p15 { padding-top:15px;padding-right:15px;padding-bottom:15px;padding-left:15px; } .p20 { padding-top:20px;padding-right:20px;padding-bottom:20px;padding-left:20px; } .p25 { padding-top:25px;padding-right:25px;padding-bottom:25px;padding-left:25px; } .p30 { padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px; } /* zero padding on all side*/ .ptb0 { padding-top:0;padding-bottom:0; } .ptb5 { padding-top:5px;padding-bottom:5px; } .ptb10 { padding-top:10px;padding-bottom:10px; } .ptb15 { padding-top:15px;padding-bottom:15px; } .ptb20 { padding-top:20px;padding-bottom:20px; } .ptb25 { padding-top:25px;padding-bottom:25px; } .ptb30 { padding-top:30px;padding-bottom:30px; } /* Padding top and bottom */ .prl0 { padding-right:0;padding-left:0; } .prl4 { padding-right:4px;padding-left:4px; } .prl5 { padding-right:5px;padding-left:5px; } .prl10 { padding-right:10px;padding-left:10px; } .prl15 { padding-right:15px;padding-left:15px; } .prl20 { padding-right:20px;padding-left:20px; } .prl25 { padding-right:25px;padding-left:25px; } .prl30 { padding-right:30px;padding-left:30px; } /* Padding left and right */ .pt0 { padding-top: 0px; } .pt5 { padding-top: 5px; } .pt10 { padding-top: 10px; } .pt15 { padding-top: 15px; } .pt20 { padding-top: 20px; } .pt25 { padding-top: 25px; } .pt30 { padding-top: 30px; } .pt40 { padding-top: 40px; } /* padding top */ .pr0 { padding-right: 0px; } .pr5 { padding-right: 5px; } .pr10 { padding-right: 10px; } .pr15 { padding-right: 15px; } .pr20 { padding-right: 20px; } .pr25 { padding-right: 25px; } .pr30 { padding-right: 30px; } /* padding right */ .pb5 { padding-bottom: 5px; } .pb0 { padding-bottom: 0px; } .pb10 { padding-bottom: 10px; } .pb15 { padding-bottom: 15px; } .pb20 { padding-bottom: 20px; } .pb25 { padding-bottom: 25px; } .pb30 { padding-bottom: 30px; } /* padding bottom */ .pl0 { padding-left: 0px; } .pl5 { padding-left: 5px; } .pl8 { padding-left: 8px; } .pl9 { padding-left: 9px; } .pl10 { padding-left: 10px; } .pl15 { padding-left: 15px; } .pl20 { padding-left: 20px; } .pl25 { padding-left: 25px; } .pl30 { padding-left: 30px; } /* padding left */ /*************************************** CLIENT SPECIFIC STYLES ****************************************/ .m-hide, .m-hide div, .m-hide table, .m-hide tr, .m-hide td { display: none; font-size: 0; max-height: 0; line-height: 0; } /* Used to hide elements for mobile */ #outlook a {padding:0;} /* Force Outlook to provide a "view in browser" menu link. */ body{width:100% !important; -webkit-text-size-adjust:100%; -ms-text-size-adjust:100%; margin:0; padding:0;} /* Prevent Webkit and Windows Mobile platforms from changing default font sizes.*/ .ExternalClass {width:100%;} /* Force Hotmail to display emails at full width */ .ExternalClass, .ExternalClass p, .ExternalClass span, .ExternalClass font, .ExternalClass td, .ExternalClass div {line-height: 100%;} /* Forces Hotmail to display normal line spacing. More on that: http://www.emailonacid.com/forum/viewthread/43/ */ .yshortcuts { color: inherit; border-bottom: none !important;} /* Yahoo fix for shortcuts*/ #backgroundTable { background-color: #cccccc; margin:0; padding:0; width:100% !important; line-height: 100% !important;} /* end reset */ img {display:block; outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; border:none;font-size: 9px;} /* Some sensible defaults for images*/ </style> <style type="text/css" data-ignore="ignore"> /*************************************** GLOBAL STYLES ****************************************/ * { line-height: inherit; } /* Prevent Outlook.com from overriding line-height */ body { font-family: helvetica, arial, sans-serif; font-size: 12px;color: #4D4D4F;line-height: 16px; } /* Render font family properly in Outlook */ table td {border-collapse: collapse; /*mso-line-height-rule: exactly;*/ } /* Outlook 07, 10 Padding issue fix Bring inline: No.*/ /*************************************** MOBILE STYLES ****************************************/ @media only screen and (max-width: 480px){ body[yahoo] .main-table { width: 405px !important; } body[yahoo] .main-table table { width:100% !important; margin: 0 auto !important; } body[yahoo] .block, body[yahoo] .content, body[yahoo] .safety { display: block; } /* place content you want stacked here */ body[yahoo] .hide, body[yahoo] #hide, body[yahoo] #backgroundTable .hide { display:none !important; } /* hide elements for mobile */ body[yahoo] img { width: auto !important; height: auto !important; } /* large images resize down according to their parent container size */ body[yahoo] .m-hide { font-size: 100% !important; display: block !important; max-height: none !important; line-height: 1.5 !important; background-color: #fff; } body[yahoo] .m-hide .support-links div { font-size: 100% !important; display: block !important; max-height: none !important; line-height: 1.5 !important; background-color: #711471 !important; } body[yahoo] .m-hide .support-container, body[yahoo] .m-hide .support-container table, body[yahoo] .m-hide .support-container tr { font-size: 100% !important; display: block !important; max-height: none !important; line-height: 1.5 !important; background-color: #711471 !important; } body[yahoo] .m-hide .support-container td { font-size: 100% !important; display: inline-block !important; max-height: none !important; line-height: 1.5 !important; background-color: #711471 !important; } body[yahoo] #backgroundTable .footer .m-hide { background-color: transparent !important;} body[yahoo] .legal a:first-child { border-top: 1px solid #ccc; margin: 15px 0 0 0;} body[yahoo] .legal a { display: inline-block; width: 100%; text-decoration: none; border-bottom: 1px solid #ccc; padding: 10px 0; text-align: center; } body[yahoo] .box { -webkit-box-sizing: border-box;box-sizing: border-box; padding: 0 10px; } body[yahoo] .box2 { -webkit-box-sizing: border-box;box-sizing: border-box; padding: 0 16px; } body[yahoo] p:last-child { margin-bottom: 0;padding-bottom: 10px;} body[yahoo] .safety { -webkit-background-size: cover;background-size: cover; width: 100% !important; } body[yahoo] .callout .box { padding: 10px !important;} /*body[yahoo] .h2 { font-size: 17px !important; line-height: 21px;}*/ body[yahoo] .chart-inner table { width: auto !important;} body[yahoo] .support-links { background-color: #e2ebf4 !important; padding: 20px !important;} body[yahoo] .support-container { background-color: #711471 !important; padding: 10px !important; border-radius: 10px !important; } body[yahoo] .support-container p, body[yahoo] .support-container td { color: #ffffff !important; vertical-align: top !important; } body[yahoo] .mar-8 {margin-right: 8px !important;} body[yahoo] .m-pt5 { padding-top: 5px !important;} } </style> </head> <body yahoo="fix"> <table align="center" border="0" cellpadding="0" cellspacing="0" id="backgroundTable" width="100%">  <tr> <td class="m-hide" id="hide" style="color:#cccccc;">Now Enrolling: Ph II Anti-PDL1 BLADDER Clinical Trial A Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (UBC) (NCT02108652, Study ID GO29293)</td> </tr>  <tr> <td class="main-td pb20"> <table class="main-table" align="center" bgcolor="#cccccc" border="0" cellpadding="0" cellspacing="0" width="600">  <tr> <td class="preheader ptb10"> <table align="center" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="center"> <webversion class="webversion"> <span>view web and mobile version</span> </webversion> </td> </tr> </table> </td> </tr>   <tr> <td class="header"> <table bgcolor="#711471" align="center" border="0" cellpadding="20" cellspacing="0" width="100%"> <tr> <td> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td class="h1 pt10">Now Enrolling: Ph II Anti-PDL1 BLADDER Clinical Trial</td> </tr>  <tr> <td class="h2 ptb5">A Study of <strong>MPDL3280A</strong> (an Engineered <strong>Anti-PDL1</strong> Antibody) in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (UBC) (NCT02108652, Study ID GO29293)</td> </tr>  </table> </td> </tr> </table> </td> </tr>   <tr> <td bgcolor="#ffffff" > <table class="box" align="center" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr>  <td class="content" valign="top"> <table align="center" border="0" cellpadding="0" cellspacing="0" width="405"> <tr> <td> <table align="center" border="0" cellpadding="0" cellspacing="0" width="376"> <tr> <td width="257"> <table align="center" border="0" cellpadding="0" cellspacing="0" width="257"> <tr> <td class="h3 m-pt5">Trial Design:</td> </tr>  <tr> <td class="ul pb5"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td class="li" valign="top">•</td> <td>A Phase II, multicenter, open-label,<br /> single‑arm study designed to evaluate the effect of MPDL3280A treatment in patients with locally advanced or metastatic UBC</td> </tr> </table> </td> </tr>  </table>  </td> <td align="right"> <img class="mar-8" src="http://prod.campaign-monitor.gene.s3.amazonaws.com/biooncology/bio-bla1/20140505/heart.gif" alt="" width="116" height="114" /> </td> </tr> </table>  </td> </tr> </table>  <table align="center" border="0" cellpadding="0" cellspacing="0" width="405"> <tr> <td>  <table align="center" border="0" cellpadding="0" cellspacing="0" width="376"> <tr> <td class="image"> <img src="http://prod.campaign-monitor.gene.s3.amazonaws.com/biooncology/bio-bla1/20140505/chart.gif" alt="" width="376" height="63"/> </td> </tr>   <tr> <td class="ptb20"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td class="hr"> </td> </tr> </table> </td> </tr>  <tr> <td class="h3">Primary Endpoint:</td> </tr>  <tr> <td class="ul"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td class="li" valign="top">•</td> <td>Objective response rate</td> </tr> </table> </td> </tr>  <tr> <td class="h3">Secondary Endpoints:</td> </tr>  <tr> <td class="ul"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td class="li" valign="top">•</td> <td>Duration of response</td> </tr> <tr> <td class="li" valign="top">•</td> <td>Progression-free survival</td> </tr> <tr> <td class="li" valign="top">•</td> <td>Overall survival</td> </tr> <tr> <td class="li" valign="top">•</td> <td>Safety: incidence of adverse events</td> </tr> <tr> <td class="li" valign="top">•</td> <td>Incidence of antitherapeutic antibodies to MPDL3280A</td> </tr> <tr> <td class="li" valign="top">•</td> <td>Maximum serum concentration (C<sub>max</sub>) of MPDL3280A</td> </tr> </table> </td> </tr>  <tr> <td class="h3">Key Inclusion Criteria<sup>2</sup>:</td> </tr>  <tr> <td class="ul"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td class="li" valign="top">•</td> <td>Documented locally advanced or metastatic transitional cell carcinoma of the urothelium</td> </tr> <tr> <td class="li" valign="top">•</td> <td>Representative tumor specimens</td> </tr> <tr> <td class="li" valign="top">•</td> <td>ECOG performance status of 0-1</td> </tr> <tr> <td class="li" valign="top">•</td> <td>Life expectancy ≥12 weeks</td> </tr> <tr> <td class="li" valign="top">•</td> <td>Measurable disease, as defined by RECIST v1.1</td> </tr> <tr> <td class="li" valign="top">•</td> <td>Adequate hematologic and end-organ function</td> </tr> <tr> <td class="li" valign="top">•</td> <td>Refractory or ineligible for platinum-based chemotherapy</td> </tr> </table> </td> </tr>  <tr> <td class="h3">Key Exclusion Criteria<sup>2</sup>:</td> </tr>  <tr> <td class="ul"> <table border="0" cellpadding="0" cellspacing="0"> <tr> <td class="li" valign="top">•</td> <td>History of autoimmune disease</td> </tr> <tr> <td class="li" valign="top">•</td> <td>Active hepatitis B or hepatitis C</td> </tr> <tr> <td class="li" valign="top">•</td> <td>HIV-positive</td> </tr> <tr> <td class="li" valign="top">•</td> <td>Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1</td> </tr> <tr> <td class="li" valign="top">•</td> <td>Prior treatment with CD137 agonists, or immune checkpoint blockade therapies, including anti‑CTLA4, anti‑PD1, and anti‑PDL1</td> </tr> </table> </td> </tr>  <tr> <td class="footnote pb10"> <table class="light-gray" border="0" cellpadding="0" cellspacing="0"> <tr> <td class="li" valign="top">1.</td> <td>Product under investigation has not been approved for use outside of the clinical trial setting. This information is presented only for the purpose of providing an overview of the clinical trial and should not be construed as a recommendation for use of any product for unapproved purposes.</td> </tr> <tr> <td class="li" valign="top">2.</td> <td>For more information on trial inclusion and exclusion criteria, visit <a class="light-gray underline" href="http://www.antipdl1clinicaltrials.com/hcp/?c=[MEDIA_ORIG_CD]&moc=[MEDIA_ORIG_CD]&cid=bio_EM_MBBIUA7100">antiPDL1ClinicalTrials.com/hcp</a>.</td> </tr> </table> </td> </tr>  </table>   </td> </tr> </table> </td>   <td class="safety box hide" bgcolor="#e2ebf4" valign="top" width="195"> <table align="center" border="0" cellpadding="0" cellspacing="0" width="167"> <tr> <td class="ptb20"> <table align="center" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td class="image hide" bgcolor="#711471"> <img src="http://prod.campaign-monitor.gene.s3.amazonaws.com/biooncology/bio-pdl1/20140218/round-top.gif" width="175" height="11"/> </td> </tr>  <tr> <td class="callout"> <table class="box" bgcolor="#711471" align="center" border="0" cellpadding="8" cellspacing="0" width="100%"> <tr> <td class="ptb0"> <table align="center" border="0" cellpadding="0" cellspacing="0"> <tr> <td class="h3 white pb15">For More Information</td> </tr>  <tr> <td class="ul"> <table class="white" border="0" cellpadding="0" cellspacing="0"> <tr> <td class="li" valign="top"><em>Call:</em></td> <td><a class="no-link white" href="tel:18886626728">1-888-662-6728</a><br />(Genentech Trial<br />Information Support<br />Line–US only)</td> </tr> <tr> <td class="li" valign="top"><em>Visit:</em></td> <td><a class="white" href="http://www.antipdl1clinicaltrials.com/hcp/?c=[MEDIA_ORIG_CD]&moc=[MEDIA_ORIG_CD]&cid=bio_EM_MBBIUA7100">antiPDL1Clinical<br />Trials.com/hcp</a><br />(NCT02108652)</td> </tr> <tr> <td class="li" valign="top"><em>E‑mail:</em></td> <td><a class="white" href="mailto:global.rochegenentechtrials@roche.com">global.rochegenentech<br />trials@roche.com</a><br />(GO29293)</td> </tr> </table> </td> </tr>  </table> </td> </tr> </table> </td> </tr> <tr> <td class="image hide" bgcolor="#711471"> <img src="http://prod.campaign-monitor.gene.s3.amazonaws.com/biooncology/bio-pdl1/20140218/round-bottom.gif" width="175" height="11"/> </td> </tr>  </table> </td> </tr> </table> </td>  </tr> </table> </td> </tr>   <tr class="m-hide"> <td class="m-hide support-links"> <div class="support-container"> <table> <tr> <td width="45"><em>Call:</em></td> <td><a class="no-link white" href="tel:18886626728">1-888-662-6728</a><br />(Genentech Trial Information Support Line–US only)</td> </tr> <tr> <td width="45"><em>Visit:</em></td> <td><a class="white" href="http://www.clinicaltrials.gov/ct2/show/NCT02008227?c=[MEDIA_ORIG_CD]&moc=[MEDIA_ORIG_CD]&cid=bio_EM_MBBIUA7100">antiPDL1ClinicalTrials.com/hcp</a> (NCT02108652)</td> </tr> <tr> <td width="45"><em>E‑mail:</em></td> <td><a class="white" href="mailto:global.rochegenentechtrials@roche.com">global.rochegenentechtrials@roche.com</a> (GO29293)</td> </tr> </table> </div> </td> </tr>  <tr> <td class="bt"> <table bgcolor="#ffffff" align="center" border="0" cellpadding="20" cellspacing="0" width="100%"> <tr> <td class="footnote"> <table align="center" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td class="legal pb10"> <a class="no-underline" href="http://www.gene.com/privacy-policy?c=[MEDIA_ORIG_CD]&moc=[MEDIA_ORIG_CD]&cid=bio_EM_MBBIUA7100" target="_blank"><span class="underline">Privacy Policy</span></a> <span class="linkDivider hide">|</span> <a class="no-underline" href="http://www.gene.com/terms-conditions?c=[MEDIA_ORIG_CD]&moc=[MEDIA_ORIG_CD]&cid=bio_EM_MBBIUA7100" target="_blank"><span class="underline">Terms and Conditions</span></a> <span class="linkDivider hide">|</span> <a class="no-underline" href="https://www.gene.com/contact-us?c=[MEDIA_ORIG_CD]&moc=[MEDIA_ORIG_CD]&cid=bio_EM_MBBIUA7100" target="_blank"><span class="underline">Contact Genentech</span><sup class="purple">®</sup></a> </td> </tr>  <tr> <td class="pb10">This e-mail is intended for U.S. healthcare professionals only.</td> </tr>  <tr> <td class="address pb10"> © 2014 Genentech USA, Inc. All rights reserved. <br /><a class="no-link" href="">1 DNA Way, South San Francisco, CA 94080-4990</a> </td> </tr>  <tr> <td class="p">To unsubscribe or manage your Genentech BioOncology communications, <a href="https://interactive.genentech.com/subscription/subscribers/[REF_NUM]/optout/index.html?shortLink=unsubscribe&productCode=[PROD_CD]&c=[MEDIA_ORIG_CD]&moc=[MEDIA_ORIG_CD]&cid=bio_EM_MBBIUA7100">click here</a>. </td> </tr>    </table> </td> </tr> </table> </td> </tr>  <tr> <td class="footer"> <table bgcolor="#642566" align="center" border="0" cellpadding="20" cellspacing="0" width="100%"> <tr> <td class="pt10"> <table align="center" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td class="pt25 pb20"> <table border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td class="image"> <a href="http://www.gene.com/?c=[MEDIA_ORIG_CD]&moc=[MEDIA_ORIG_CD]&cid=bio_EM_MBBIUA7100"><img src="http://prod.campaign-monitor.gene.s3.amazonaws.com/biooncology/bio-bla1/20140505/logoGenentech.gif" alt="Genentech" width="110" height="30"/></a> </td> <td class="pb10" align="right"> <a href="http://www.biooncology.com/index.html?c=[MEDIA_ORIG_CD]&moc=[MEDIA_ORIG_CD]&cid=bio_EM_MBBIUA7100"><img src="http://prod.campaign-monitor.gene.s3.amazonaws.com/biooncology/bio-bla1/20140505/logoBioOncology.gif" alt="BioOncology" width="100" height="15"></a> </td> </tr> </table> </td> </tr> <tr> <td class="m-hide hide">   </td> </tr> </table> </td> </tr> </table> </td> </tr>  </table> </td> </tr> </table>   <singleline style="font-size: 0; line-height: 0; display: none; margin: 0; padding: 0;"> </singleline> <unsubscribe style="font-size: 0; line-height: 0; display: none; margin: 0; padding: 0;"> </unsubscribe>  <script src="http://localhost:35729/livereload.js"></script> </body> </html>